SCHEMBL3753672

SCHEMBL3753672

CCOC(=O)C1c2ccccc2C(=O)N1CCc1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 4/20 0.48
TP53 P04637 2/20 0.47
KCNA5 P22460 4/20 0.45
KCNH2 Q12809 2/20 0.44
SCN9A Q15858 2/20 0.44
SCN5A Q14524 1/20 0.44
P2RX7 Q99572 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TNF P01375 1/20 0.43
LMNA P02545 1/20 0.43
HSP90AA1 P07900 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
ALOX12 P18054 1/20 0.43
CCR6 P51684 1/20 0.43
RUNX1 Q01196 1/20 0.43
CBFB Q13951 1/20 0.43
HKDC1 Q2TB90 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3892240 0.87 SCN9A (0.55) KCNA5KCNH2SCN9ASCN5AMAPT
SCHEMBL3750835 0.83 MDM2 (0.57) MDM2TP53KCNA5KCNH2SCN9A
SCHEMBL3762651 0.82 MDM2 (0.46) MDM2TP53KCNA5KCNH2SCN9A
SCHEMBL3890079 0.82 SCN9A (0.57) KCNH2SCN9ASCN5AKDM4EALDH1A1
SCHEMBL3750322 0.81 MDM2 (0.40) MDM2TP53KCNA5KCNH2SCN9A
SCHEMBL1888404 0.81 FFAR1 (0.50) P2RX7ALDH1A1MAPTHPGDFFAR1
SCHEMBL3756386 0.81 KCNA5 (0.68) MDM2TP53KCNA5KCNH2P2RX7
SCHEMBL3956190 0.79 SCN9A (0.62) KCNA5KCNH2SCN9ASCN5AMAPT
SCHEMBL3762841 0.79 KCNA5 (0.58) MDM2TP53KCNA5KCNH2SCN9A
SCHEMBL3752465 0.79 KCNA5 (0.69) MDM2TP53KCNA5KCNH2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 MDM2 3686/4885TP53 3912/4885KCNA5 69/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 MDM2 3351/4885TP53 3602/4885KCNA5 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.